Stephen Shrewsbury
Director/Board Member bij BioXpertz LLC
Profiel
Stephen Bevan Shrewsbury is currently the Director at BioXpertz LLC.
He previously worked as the Senior Director-Clinical Development at Chiron Corp., Director & Head-Senior Clinical Program at GSK Plc, Chief Medical Officer & SVP-Preclinical at Sarepta Therapeutics, Inc., Chief Medical Officer & VP-Clinical Affairs at MAP Pharmaceuticals LLC, Chief Medical Officer & SVP-Clinical Development at Adamas Pharmaceuticals LLC, and Chief Medical Officer at Impel Pharmaceuticals, Inc. He also served as the Chief Medical Officer & SVP-Clinical Development at Aquinox Pharmaceuticals, Inc. and as the Chief Medical Officer & Executive VP-Development at Fortuna Fix, Inc. Dr. Shrewsbury earned a doctorate degree from The University of Liverpool.
Actieve functies van Stephen Shrewsbury
| Bedrijven | Functie | Begin |
|---|---|---|
| BioXpertz LLC | Director/Board Member | - |
Eerdere bekende functies van Stephen Shrewsbury
| Bedrijven | Functie | Einde |
|---|---|---|
Fortuna Fix, Inc.
 Fortuna Fix, Inc. BiotechnologyHealth Technology Fortuna Fix, Inc. operates as a clinical-stage regenerative medicine firm. It develops a patented direct cell reprogramming technology platform (drNPC) and a proprietary bio-scaffolding technology (RMx), for the treatment of neurodegenerative diseases and neurotrauma. The company is headquartered in Laval, Canada. | Chief Tech/Sci/R&D Officer | 01-12-2016 |
Aquinox Pharmaceuticals, Inc.
 Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | Chief Tech/Sci/R&D Officer | 01-01-2016 |
| SAREPTA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 20-06-2011 |
| ADAMAS PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01-08-2008 |
MAP Pharmaceuticals LLC
 MAP Pharmaceuticals LLC Medical SpecialtiesHealth Technology MAP Pharmaceuticals, Inc. develops therapies and inhalation delivery technologies. The company was founded by Thomas A. Armer on July 3, 2003 and is headquartered in Irvine, CA. | Chief Tech/Sci/R&D Officer | 01-03-2008 |
Opleiding van Stephen Shrewsbury
| The University of Liverpool | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| SAREPTA THERAPEUTICS, INC. | Health Technology |
| IPI LEGACY LIQUIDATION CO | Health Technology |
| GSK PLC | Health Technology |
| Bedrijven in privébezit | 6 |
|---|---|
Chiron Corp.
 Chiron Corp. Medical SpecialtiesHealth Technology Chiron Corp. provides nucleic acid test for blood screening. Its products include tigris system, target capture system, reagent preparation incubator, and many more. The company was founded in 1981 by William J. Rutter, Edward E. Penhoet & Pablo Valenzuela and is headquartered in Emeryville, CA. | Health Technology |
MAP Pharmaceuticals LLC
MAP Pharmaceuticals LLC Medical SpecialtiesHealth Technology MAP Pharmaceuticals, Inc. develops therapies and inhalation delivery technologies. The company was founded by Thomas A. Armer on July 3, 2003 and is headquartered in Irvine, CA. | Health Technology |
Adamas Pharmaceuticals LLC
 Adamas Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. | Health Technology |
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | Health Technology |
| BioXpertz LLC | |
Fortuna Fix, Inc.
Fortuna Fix, Inc. BiotechnologyHealth Technology Fortuna Fix, Inc. operates as a clinical-stage regenerative medicine firm. It develops a patented direct cell reprogramming technology platform (drNPC) and a proprietary bio-scaffolding technology (RMx), for the treatment of neurodegenerative diseases and neurotrauma. The company is headquartered in Laval, Canada. | Health Technology |
